---
title: "Tissue-specific immune diversion limits dual PD-L1/CTLA-4 blockade efficacy in metastatic colorect"
id: "medrxiv-18-site-specific-immune-remodeling-underlies-resistance-to-dual-immune-checkpoint"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-18-site-specific-immune-remodeling-underlies-resistance-to-dual-immune-checkpoint"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.23.26365904v1?rss=1"
published_at: "2026-10-23T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Tissue-specific immune diversion limits dual PD-L1/CTLA-4 blockade efficacy in metastatic colorect
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-18-site-specific-immune-remodeling-underlies-resistance-to-dual-immune-checkpoint
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.23.26365904v1?rss=1)
- **Published At:** 2026-10-23T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The phase II SERPENTINE trial evaluated dual **PD-L1** and **CTLA-4** blockade in metastatic colorectal cancer (mCRC) with proficient mismatch repair and microsatellite stability (**MSS mCRC**). The investigators integrated paired pre- and on-treatment single-cell transcriptomics and T-cell receptor (TCR) profiling across metastatic biopsies and deep peripheral blood TCR sequencing. - The dataset comprised 388,196 single cells and 95,617 intratumoral clonotypes, with matched peripheral blood sequencing yielding 57,902,418 clonotypes. These numbers were reported by the study team. - Clinical benefit from dual immune checkpoint inhibition was observed only in patients without liver metastases; every patient with liver metastases experienced progression on therapy, according to the authors. - Systemic T-cell priming occurred after therapy regardless of metastatic site, mobilizing therapy-expanded clones that trafficked to both lung and liver lesions, investigators reported. - In lung metastases, expanded clones concentrated into tissue-resident, proliferative, tumor-reactive CD8+ T-cell states, consistent with on-target intratumoral engagement. - In liver metastases, the same therapy-driven activation was dispersed: the cohort showed expansion of regulatory T cells and suppressive myeloid populations, diversified TCR repertoires, and fragmentation of exhaustion-associated T-cell gene networks. - Cross-lineage co-expression analysis indicated tumor proliferation increased alongside cytotoxic CD8+ programs, implying effector engagement that nevertheless failed to restrain tumor growth in liver lesions. - The authors conclude resistance in liver metastases reflects tissue-specific misdirection of immune activation away from productive antitumor immunity and identify multicellular immune coordination in the metastatic microenvironment as a determinant of ICI efficacy. - The source reports that raw and processed single-cell sequencing data will be made publicly available upon final publication; clinical trial registration is NCT06680739. - The study team noted remaining mechanistic questions about whether local microenvironmental interventions can redirect systemic T-cell priming toward productive tumor control in hepatic lesions; the source did not report interventional rescue experiments or specific therapeutic strategies to overcome the liver-associated resistance.
## Clinical Analysis & Structured Key Points
Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer | medRxiv Skip to main content Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer View ORCID Profile Iosune Baraibar , View ORCID Profile Samuel Morabito , View ORCID Profile Gerard Deuner-Cos , View ORCID Profile Ginevra Caratù , View ORCID Profile Juan Luis Melero , View ORCID Profile Miren Berasategi , Marta Soto , Marta Grzelak , View ORCID Profile Paula Nieto , View ORCID Profile Davide Maspero , Francesc Salvà , Nadia Saoudi , View ORCID Profile Javier Ros , Raquel Pérez-López , View ORCID Profile Alena Gros , View ORCID Profile Guillermo Villacampa , View ORCID Profile Nuria Roson , Javier Carmona , Ariadna García , Arthur Lambert , Nadia Martinez-Martin , Patricia Casbas-Hernandez , Jorge Zeron-Medina , View ORCID Profile Josep Tabernero , View ORCID Profile Asaf Rotem , View ORCID Profile Juan C. Nieto , View ORCID Profile Elena Élez , View ORCID Profile Holger Heyn doi: https://doi.org/10.64898/2026.10.23.26365904 Iosune Baraibar 1 Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Gastrointestinal Tract Tumors Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Iosune Baraibar Samuel Morabito 2 Centro Nacional de Análisis Genómico; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Samuel Morabito Gerard Deuner-Cos 3 Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain; Universitat de Barcelona (UB), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Gerard Deuner-Cos Ginevra Caratù 4 Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ginevra Caratù Juan Luis Melero 5 Omniscope, Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Juan Luis Melero Miren Berasategi 4 Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Miren Berasategi Marta Soto 5 Omniscope, Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marta Grzelak 5 Omniscope, Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Paula Nieto 6 Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Paula Nieto Davide Maspero 4 Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Davide Maspero Francesc Salvà 1 Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Gastrointestinal Tract Tumors Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nadia Saoudi 1 Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Gastrointestinal Tract Tumors Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Javier Ros 1 Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Gastrointestinal Tract Tumors Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Javier Ros Raquel Pérez-López 7 Radiomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alena Gros 8 Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Alena Gros Guillermo Villacampa 9 Statistical Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Guillermo Villacampa Nuria Roson 10 Radiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Nuria Roson Javier Carmona 11 Gastrointestinal Tract Tumors Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ariadna García 11 Gastrointestinal Tract Tumors Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Arthur Lambert 12 AstraZeneca, Translational Medicine, Waltham MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nadia Martinez-Martin 13 AstraZeneca, External Research and Development, Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Patricia Casbas-Hernandez 14 AstraZeneca, Medical Affairs, Gaithersburg MD, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jorge Zeron-Medina 12 AstraZeneca, Translational Medicine, Waltham MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Josep Tabernero 15 Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Gastrointestinal Tract Tumors Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro de Investigación Bi; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Josep Tabernero Asaf Rotem 12 AstraZeneca, Translational Medicine, Waltham MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Asaf Rotem Juan C. Nieto 4 Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Juan C. Nieto Elena Élez 15 Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Gastrointestinal Tract Tumors Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Centro de Investigación Bi; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Elena Élez For correspondence: meelez{at}vhio.net Holger Heyn 16 Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain; Universitat de Barcelona (UB), Barcelona, Spain; Omniscope, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Holger Heyn Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Immune checkpoint inhibitors (ICIs) have limited efficacy in metastatic colorectal cancer (mCRC) with proficient mismatch repair and microsatellite stability (pMMR/MSS), with liver metastases emerging as a dominant determinant of resistance. Whether this reflects a failure to activate antitumor immunity or a failure to direct it remains unclear. We investigated this in the phase II SERPENTINE trial of dual PD-L1 and CTLA-4 blockade by integrating paired pre-treatment and on-treatment single-cell transcriptomic and T-cell receptor (TCR) profiling (388,196 cells; 95,617 clonotypes) metastatic biopsies with deep TCR sequencing of matched peripheral blood (57,902,418 clonotypes). In MSS mCRC, clinical benefit was restricted to patients without liver metastases, whereas all patients with liver metastases progressed. Dual ICI induced systemic T-cell priming regardless of metastatic site, mobilizing therapy-expanded clones that trafficked to both lung and liver lesions, but the fate of this response was determined locally. In lung metastases, therapy-specific clones focused into tissue-resident, proliferative, tumor-reactive CD8+ T-cell states. In liver metastases, the same activation was dispersed: regulatory T cells and suppressive myeloid populations expanded, TCR repertoires diversified, and exhaustion-associated T-cell gene networks fragmented. Cross-lineage co-expression analysis further revealed that tumor proliferation increased in concert with cytotoxic CD8+ T-cell programs, indicating effector engagement that fails to restrain tumor growth. These findings show that resistance to ICI in liver metastases arises from tissue-specific misdirection of immune activation away from productive antitumor immunity, identifying multicellular coordination of the immune response in the metastatic microenvironment as a determinant of therapeutic efficacy. Competing Interest Statement IB reports accommodation and travel expenses from Amgen, Merck, Sanofi, and Servier; and personal financial interests as Honoraria, Consulting or Advisory Role from Agenus, Amgen, AstraZeneca, Sai-Med and Servier. HH is co-founder and Chief Scientific Officer of Omniscope, Founder of Codex Insights, scientific advisory board member of Nanostring, Bruker and MiRXES, consultant to Moderna and Singularity and received an honorarium from Genentech. EE reports personal financial interests as Honoraria, Consulting or Advisory Role, and Speakers Bureau: Agenus, Amgen, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Cure Teq AG, GlaxoSmithKline, Hoffman La Roche, Janssen, Johnson&Johnson, Lilly, Medscape, Merck Serono, MSD, Nordic Group BV, Novartis, Organon, Pfizer, Pierre Fabre, Repare Therapeutics Inc., RIN Institute Inc., Rottapharm Biotech, Sanofi, Seagen International GmbH, Servier, and Takeda. JCN is a scientific consultant to Omniscope and scientific advisory board member of Biocompare. JT reports personal financial interest in form of scientific consultancy role for Accent Therapeutics, Alentis Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Carina Biotech, Cartography Biosciences, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, Johnson & Johnson/Janssen, Larkspur Biosciences, Lilly, Marengo Therapeutics, Menarini, Merus, MSD, Novartis, Ono Pharma USA, Peptomyc, Pfizer, Pierre Fabre, Quantro Therapeutics, Scandion Oncology, Scorpion Therapeutics, Servier, Sotio Biotech, Syntelios AG, Taiho, Takeda Oncology and Tolremo Therapeutics. Stocks: Alentis Therapeutics, Oniria Therapeutics, 1TRIALSP and Pangaea Oncology. AGros received funding from Merck for the submitted work. In addition, A. Gros has a patent for E-059-2013/0 licensed and with royalties paid from Intima Bioscience Inc., Intellia Therapeutics, Inc., Tailored Therapeutics, LLC, Cellular Biomedicine Group, Inc., and Geneius Biotechnology, Inc.; a patent for E-085-2013/0 licensed and with royalties paid from Intima Bioscience Inc., Intellia Therapeutics, Inc., and Geneius Biotechnology, Inc.; and a patent for E-149-2015/0 licensed and with royalties paid from Intima Bioscience Inc., Intellia Therapeutics, Inc., and Tailored Therapeutics, LLC. AGarcia reports accommodation and travel expenses from Merck. GV has received speaker fee from MSD, Pfizer, GSK, PharmaMar, Giliead, AstraZeneca and Pierre Fabre, and received consultant fees from Reveal Genomics. FS reports personal financial interests, honoraria for advisory role, travel grants, research grants (past 5 years) from Sanofi Aventis, Amgen, Merck Serono, Servier, Bristol-Myers Squibb, Terumo, MSD, Takeda. JR reports personal speaker honoraria from Sanofi, Pfizer, Takeda, BMS, Merck and Amgen; and accommodation expenses from Pierre Fabre, Servier, Takeda, Amgen, and Merck. NS reports travel and accommodation expenses from Merck and Amgen. Speakers Bureau: From AMGEN and Medistream OncoBites. RPL reports receiving research funding from AstraZeneca PLC (global) and Roche Farma S.A. (Spain). RPL also declares a consulting/advisory role with AstraZeneca PLC (global). Additionally, she holds non-remunerated positions as a member of the RECIST Working Group; head of the Cancer Core Europe Imaging Task Force; head of Oncological Imaging for the Spanish Society of Medical Imaging (SERAM); and head of the Research Committee of the European Society of Radiology (ESR). AR, JZM, AL, NMM and PCH are employees of AstraZeneca and have equity in AstraZeneca. JLM, MS, and MG are employees of Omniscope. Clinical Trial NCT06680739 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Hospital Universitari Vall d'Hebron Research Ethics Committee gave ethical approval for this work (approval number: PR(AG)144/201). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All raw and processed single-cell sequencing data will be made publicly available upon final publication. Additional single-cell datasets from published studies were obtained via the following accessions: the Chen et al 202425 scRNA-seq + scTCR-seq dataset was collected from the Gene Expression Omnibus at accession GSE236581. The cancer genome atlas (TCGA) CRC bulk RNA-seq dataset was collected using the R package TCGAbiolinks. Funder Information Declared Generalitat de Catalunya, https://ror.org/01bg62x04 , Joan Oró Fi predoctoral fellowship, 2026 F1-1 01103 , Suport Grups de Recerca AGAUR, 2021-SGR2021-01216 European Molecular Biology Organization, https://ror.org/04wfr2810 , Postdoctoral Fellowship, ALTF-834-2024 European Union , 848028 , 101072891 , CP25/00092 European Research Council , 810287 Ministerio de Ciencia, Innovación y Universidades , PID2020-115439GB-I00 , PID2023 -148687OB-I00 , PID2024-161652OB-I00 , PLEC2021-007654 , PCI2022-133012 , PID2020-118529RB-I00 Fundación Bancaria Caixa d’Estalvis i Pensions de Barcelona , HR22-0031 , HR22-0172 , HR25-00861 Asociación Española Contra el Cáncer , CATALYST 0000000014 , IDEAS197PORT , PRYCO211023SERR Instituto de Salud Carlos III , MS15/00058 , PI17/01085 Fundación BBVA , CAIMI-II 53/2021 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted October 23, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer Iosune Baraibar , Samuel Morabito , Gerard Deuner-Cos , Ginevra Caratù , Juan Luis Melero , Miren Berasategi , Marta Soto , Marta Grzelak , Paula Nieto , Davide Maspero , Francesc Salvà , Nadia Saoudi , Javier Ros , Raquel Pérez-López , Alena Gros , Guillermo Villacampa , Nuria Roson , Javier Carmona , Ariadna García , Arthur Lambert , Nadia Martinez-Martin , Patricia Casbas-Hernandez , Jorge Zeron-Medina , Josep Tabernero , Asaf Rotem , Juan C. Nieto , Elena Élez , Holger Heyn medRxiv 2026.10.23.26365904; doi: https://doi.org/10.64898/2026.10.23.26365904 Share This Article: Copy Citation Tools Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer Iosune Baraibar , Samuel Morabito , Gerard Deuner-Cos , Ginevra Caratù , Juan Luis Melero , Miren Berasategi , Marta Soto , Marta Grzelak , Paula Nieto , Davide Maspero , Francesc Salvà , Nadia Saoudi , Javier Ros , Raquel Pérez-López , Alena Gros , Guillermo Villacampa , Nuria Roson , Javier Carmona , Ariadna García , Arthur Lambert , Nadia Martinez-Martin , Patricia Casbas-Hernandez , Jorge Zeron-Medina , Josep Tabernero , Asaf Rotem , Juan C. Nieto , Elena Élez , Holger Heyn medRxiv 2026.10.23.26365904; doi: https://doi.org/10.64898/2026.10.23.26365904 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (633) Allergy and Immunology (914) Anesthesia (345) Cardiovascular Medicine (4943) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (671) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1667) Epidemiology (16161) Forensic Medicine (35) Gastroenterology (1236) Genetic and Genomic Medicine (7209) Geriatric Medicine (747) Health Economics (1091) Health Informatics (5222) Health Policy (1456) Health Systems and Quality Improvement (1812) Hematology (597) HIV/AIDS (1370) Infectious Diseases (except HIV/AIDS) (16426) Intensive Care and Critical Care Medicine (1192) Medical Education (690) Medical Ethics (156) Nephrology (739) Neurology (7497) Nursing (375) Nutrition (1114) Obstetrics and Gynecology (1281) Occupational and Environmental Health (1031) Oncology (3708) Ophthalmology (1079) Orthopedics (401) Otolaryngology (462) Pain Medicine (493) Palliative Medicine (142) Pathology (717) Pediatrics (1844) Pharmacology and Therapeutics (749) Primary Care Research
## Related Clinical Research

- [Camupepimut (ELI-002 7P) in KRAS-mutant PDAC: Phase 2 AMPLIFY-7P results](https://medichelpline.com/clinical-feed/nature-1-lymph-node-targeted-mkras-specific-amphiphile-vaccine-in-pancreatic-cancer-the.md)
- [Chromosomal instability drives continual flux in cancer genomes: rates, distribution, and ploidy l](https://medichelpline.com/clinical-feed/biorxiv-9-chromosomal-instability-drives-continual-flux-in-cancer-genomes.md)
- [Cardiorespiratory fitness and sex modify colorectal cancer–suppressive effects of post-exercise se](https://medichelpline.com/clinical-feed/biorxiv-7-cardiorespiratory-fitness-and-sex-impact-the-colorectal-cancer-suppressive.md)
- [MSI‑High Colorectal Cancer in an Adolescent: Integrated Surgical, Molecular, and Adjuvant Manageme](https://medichelpline.com/clinical-feed/pubmed-42892709.md) (DOI: 10.12659/AJCR.953248)
- [CXCL14+ fibroblasts drive IBD-associated fibrosis and cancer through collagen IV–SPP1+ macrophage](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-cxcl14-fibroblasts-promote-development-of-ibd-associated-fibrosis-and-cancer-by.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.